Lexicon Pharmaceuticals (LXRX) Interest Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Interest Expenses for 17 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 44.88% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (down 68.38% YoY), while the FY2025 annual figure was $11.6 million, down 97.23% from the prior year.
• Interest Expenses grew to $4.3 million in Q1 2026 per LXRX's latest filing, from $2.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $10.3 million in Q3 2023 and bottomed at -$4.5 million in Q4 2022.
• Historically, Interest Expenses has averaged $3.6 million across 5 years, with a median of $3.9 million in 2024.
• Annual changes were most pronounced in 2022 — Interest Expenses plunged 4913.98% — and 2023, when it jumped 1555.45%.
• Lexicon Pharmaceuticals' Interest Expenses stood at -$4.5 million in 2022, then surged by 241.48% to $6.3 million in 2023, then plunged by 39.09% to $3.9 million in 2024, then plunged by 47.36% to $2.0 million in 2025, then jumped by 111.72% to $4.3 million in 2026.
• Business Quant data shows LXRX's Interest Expenses at $4.3 million in Q1 2026, $2.0 million in Q4 2025, and $4.5 million in Q3 2025.